Muestra la distribución de la producción WoS, Scopus y SciELO del autor.
Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.
| Firmas del autor | |
| Nombre | MELLA, PABLO FERNANDO GONZALEZ |
| Género | Hombre |
| Área Principal WOS | Oncology; |
| Afiliación Principal | Universidad De Valparaíso |
Publicaciones en Chile
Citas Totales
Afiliaciones Chilenas
| WOS | #Pub |
|---|---|
| Oncology | 2 |
| Scopus | #Pub |
|---|---|
| Oncology | 2 |
| Cancer Research | 2 |
| SciELO | #Pub |
|---|
| Institución | # Pub |
|---|---|
| Universidad De Valparaíso | 1 |
| Fdn Arturo Lopez Perez | 1 |
| Fundación Arturo López Pérez | 1 |
| Instituto Oncológico | 1 |
| Inst Oncol | 1 |
| Título | Año | Citas | Tipo | Revista | Indexada |
|---|---|---|---|---|---|
| Phase Iii Trial Of Ipilimumab Combined With Paclitaxel And Carboplatin In Advanced Squamous Non Small Cell Lung Cancer | 2017 | 286 | artículo de investigación | Journal Of Clinical Oncology | WoS Scopus |
| Randomized, Double Blind, Phase Iii Trial Of Ipilimumab Versus Placebo In Asymptomatic Or Minimally Symptomatic Patients With Metastatic Chemotherapy Naive Castration Resistant Prostate Cancer | 2017 | 557 | artículo de investigación | Journal Of Clinical Oncology | WoS Scopus |
| Palabra Clave | #Pub |
|---|---|
| open-label | 2 |
| infiltration | 1 |
| survival analysis | 1 |
| recommendations | 1 |
| plus dacarbazine | 1 |
| nivolumab plus ipilimumab | 1 |
| naive patients | 1 |
| multicenter | 1 |
| melanoma | 1 |
| management | 1 |
| 1st-line treatment | 1 |
| immunotherapy | 1 |
| enzalutamide | 1 |
| ctla-4 blockade | 1 |
| chemotherapy | 1 |
| cd8(+) t-cells | 1 |
| adverse events | 1 |
| advanced melanoma | 1 |
| abiraterone acetate | 1 |